Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

OCRELIZUMAB vs UBLITUXIMAB: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

OCRELIZUMAB vs UBLITUXIMAB: Safety Overview

Metric OCRELIZUMAB UBLITUXIMAB
Total FAERS Reports 56,186 1,582
Deaths Reported 1,406 27
Death Rate 2.5% 1.7%
Hospitalizations 10,364 213
Average Patient Age 47.2 yrs 49.7 yrs
% Female Patients 72.5% 73.4%
Manufacturer Genentech, Inc. TG Therapeutics, Inc.
Route INTRAVENOUS INTRAVENOUS
Marketing Status Prescription N/A